June 28, 2024
(press release)
–
The Centers for Medicare & Medicaid Services June 28 announced the request for state applications for the Cell and Gene Therapy Access Model. The CGT Access Model will test whether a CMS-led approach to developing and administering outcomes-based agreements for cell and gene therapies improves Medicaid beneficiaries’ health outcomes, broadens access to innovative treatment and reduces health care expenditures. The model, announced in January, will initially focus on gene therapies for sickle cell disease. CMS already released a request for applications for manufacturers in March and anticipates releasing a notice of funding opportunity for states later this summer.
* All content is copyrighted by Industry Intelligence, or the original respective author or source. You may not recirculate, redistrubte or publish the analysis and presentation included in the service without Industry Intelligence's prior written consent. Please review our terms of use.
